A Proof-of-concept Study of Poliovirus Vaccine (IPV) Activity to Induce an Immune Response That Cross-reacts With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2)
A total of 300 healthy volunteers between the ages of 18 and 80 with no previous history of COVID-19 will be entered into the study and will receive IPV by injection on Day 1. Blood specimens collected pre-inoculation will be tested for cross-reactivity to poliovirus and SARS-CoV-2 by Western blot. An additional specimen will be collected on Day 28 post-inoculation and, likewise tested for cross-reactivity to poliovirus and SARS-CoV-2.
The number of subjects with an immune response to SARS-CoV-2 antigens following inoculation with IPV will be summarized.
100 项与 E Mo Biology, Inc. 相关的临床结果
0 项与 E Mo Biology, Inc. 相关的专利（医药）
100 项与 E Mo Biology, Inc. 相关的药物交易
100 项与 E Mo Biology, Inc. 相关的转化医学
